Cash/Burn From SEC Filing For Period: 

Q1 '20

ICPT

Intercept Pharmaceuticals

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH).

Cash

$549M

Burn Rate

-$93M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Ocaliva

Primary Sclerosing Cholangitis

Phase 4

TBD

Ocaliva

Adult nonalcoholic steatohepatitis (NASH)

PDUFA Priority Review

Jun 26, 2020

Ocaliva

Biliary Atresia

Phase 2

TBD

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon